What is Immunic, Inc. (IMUX) stock price today?

Immunic, Inc. (IMUX) is currently trading at $8.19, up 8.33% today.

What is IMUX P/E ratio?

Immunic, Inc.'s P/E ratio is -1.59. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IMUX return on equity (ROE)?

Immunic, Inc.'s return on equity (ROE) is -157.89%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Immunic, Inc.'s market cap?

Immunic, Inc. has a market capitalization of $111.56M.

NASDAQ · Biotechnology

Immunic, Inc. (IMUX) Stock

$8.19 +8.33% NASDAQ: IMUX Healthcare

Valuation

Metric	Value
Price	$8.19
Market Cap	$111.56M
P/E Ratio	-1.59
P/B Ratio	2.54
P/S Ratio	0.00
EPS (TTM)	$-6.24
52-Week High	$17.43
52-Week Low	$5.06
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-157.89%
ROA	-70.09%
ROCE	-92.16%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.14
Current Ratio	0.74

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-92.0M	$-119.0M	$-99.0M	$-98.0M	$-103.0M
Net Profit	$-93.0M	$-120.0M	$-94.0M	$-101.0M	$-97.0M
EPS	$-39.30	$-37.84	$-21.12	$-10.03	$-6.24
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$139.0M	$128.0M	$54.0M	$41.0M	$24.0M
Total Liabilities	$12.0M	$14.0M	$25.0M	$22.0M	$31.0M
Cash	$87.0M	$107.0M	$47.0M	$36.0M	$15.0M
Borrowings	$1.0M	$2.0M	$1.0M	$1.0M	$1.0M

Latest News

Immunic to Participate in Investor Conferences in July PR Newswire · Jul 9, 2026 Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire · Jun 10, 2026 Immunic presents new vidofludimus calcium data at multiple sclerosis conference Proactive · May 28, 2026 Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR Newswire · May 28, 2026 Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials Proactive · May 27, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-83.0M	$-65.0M	$-71.0M	$-85.0M	$-86.0M
Investing Cash Flow	$0	$-10.0M	$9.0M	$-1.0M	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-41.0M	$20.0M	$-60.0M	$-11.0M	$-20.0M
Free Cash Flow	$-83.0M	$-65.0M	$-71.0M	$-85.0M	$-86.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	0.45
FCF Yield	-84.72%
Quick Ratio	5.05
Interest Coverage	0.00
Return 1Y	74.88%
Return 3Y	-41.94%
Return 5Y	-84.27%

Ownership

Insiders Held0.97%

Institutions Held46.90%

Institutions Float Held47.37%

Institutional Holder	Shares	Report Date
Marshall Wace LLP	952,966	2026-03-31
Aberdeen Group plc	824,394	2026-03-31
BVF Inc.	765,297	2026-03-31
Avidity Partners Management, LP	669,941	2026-03-31
Vanguard Capital Management LLC	513,832	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Immunic, Inc.

Immunic, Inc. is led by CEO Daniel Vitt, employs 91 people, headquartered in US, publicly traded since 2014.

Immunic, Inc. (IMUX) stock trades at $8.19 with a market capitalization of $111.56M. The stock is valued at a price-to-earnings (P/E) ratio of -1.59, price-to-book of 2.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.06 and $17.43, and currently trades 53.0% below its 52-week high.

On profitability, Immunic, Inc. generates a return on equity (ROE) of -157.89%, return on capital employed of -92.16%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides